Drug-Induced Cheilitis Study: 38 Drugs from 5,007 FDA Reports

This study analyzes 5,007 cheilitis adverse event reports from the FDA Adverse Event Reporting System (2004–2025). It identifies 38 pharmaceuticals significantly associated with cheilitis, with isotretinoin most frequently reported and crisaborole showing the strongest signal. The analysis integrates pharmacovigilance, network toxicology, and molecular docking to examine underlying mechanisms.

Use Cases

• Identify high-risk drugs for cheilitis using disproportionality analysis (ROR) and logistic regression on 5,007 FDA reports.
• Analyze demographic risk factors like female sex (OR = 0.771) and protective effects of age and weight from the multivariate regression.
• Validate binding affinities (e.g., -8.1 to -6.2 kcal/mol) for drug-target pairs like afatinib-EGFR and capecitabine-IL-6 via molecular docking.
• Examine enriched signaling pathways (IL-17, TNF, PI3K-Akt) and core molecular targets (IL6, TNF, AKT1, VEGFA, STAT3) from network toxicology.
• Assess drug safety profiles using ADMET predictions, such as the high liver injury risk for four compounds versus lamotrigine's favorable profile.

Strengths

• Integrates three distinct methodologies (pharmacovigilance, network toxicology, molecular docking) on a single adverse event.
• Based on 5,007 real-world adverse event reports from the FDA Adverse Event Reporting System.
• Identifies 38 specific pharmaceuticals with significant associations to cheilitis, providing concrete drug names and risk metrics (ROR).
• Includes molecular dynamics simulation validation over 500 ns and MM/PBSA analysis for binding stability.

Limitations

• The dataset is a 11.2 KB DOCX file containing a study summary, not the underlying raw data tables or structured dataset.
• Sample data and column definitions are unavailable, limiting direct analytical reuse.
• Findings are based on spontaneous reporting system data, which is subject to under-reporting and reporting biases.

Provenance

Source

U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).

Collection Method

Disproportionality analysis, multivariate logistic regression, network toxicology, molecular docking, and 500 ns molecular dynamics simulations.

Time Range

2004–2025

Freshness

Last updated March 2026, with data coverage through 2025.

Geography

United States (data sourced from U.S. FDA).